Text Size:AAA

Bruton Tyrosine Kinase / BTK Kinase  Protein, Antibody, ELISA Kit, cDNA Clone

Bruton Tyrosine Kinase / BTK Kinase Related Area

Bruton Tyrosine Kinase / BTK Kinase Related Pathways

Bruton Tyrosine Kinase / BTK Kinase Related Protein, Antibody, cDNA Gene, and ELISA Kits

Bruton Tyrosine Kinase / BTK Kinase Related Protein, Antibody, cDNA Gene, and ELISA Kits

Featured Reagent Products

Bruton Tyrosine Kinase / BTK Kinase Summary & Protein Information

Bruton Tyrosine Kinase / BTK Kinase Background

Catalytic activity: ATP + a [protein]-L-tyrosine = ADP + a [protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-ProRule:PRU10028}.
Cofactor: Name=Zn(2+); Xref=ChEBI:CHEBI:29105; ; Note=Binds 1 zinc ion per subunit.;
Enzyme regulation: ENZYME REGULATION: Activated by phosphorylation. In primary B lymphocytes, is almost always non-phosphorylated and is thus catalytically inactive. Stimulation of TLR8 and TLR9 causes BTK activation. As a negative feedback mechanism to fine-tune BCR signaling, activated PRKCB down-modulates BTK function via direct phosphorylation of BTK at Ser-180, resulting in translocation of BTK back to the cytoplasmic fraction. PIN1, SH3BP5, and IBTK were also identified as BTK activity inhibitors. Interaction with CAV1 leads to dramatic down-regulation of the kinase activity of BTK. LFM-13A is a specific inhibitor of BTK. Dasatinib, a cancer drug acting as a tyrosine kinase inhibitor, also blocks BTK activity. {ECO:0000269|PubMed:10339589, ECO:0000269|PubMed:11577348, ECO:0000269|PubMed:11598012, ECO:0000269|PubMed:11751885, ECO:0000269|PubMed:16415872, ECO:0000269|PubMed:16644721, ECO:0000269|PubMed:17932028, ECO:0000269|PubMed:8630736}.
Subunit structure: Binds GTF2I through the PH domain. Interacts with SH3BP5 via the SH3 domain. Interacts with IBTK via its PH domain. Interacts with ARID3A, CAV1, FASLG, PIN1, TLR8 and TLR9. {ECO:0000269|PubMed:10196129, ECO:0000269|PubMed:10339589, ECO:0000269|PubMed:11577348, ECO:0000269|PubMed:11751885, ECO:0000269|PubMed:16644721, ECO:0000269|PubMed:16738337, ECO:0000269|PubMed:17932028, ECO:0000269|PubMed:19807924, ECO:0000269|PubMed:20052711, ECO:0000269|PubMed:21280133, ECO:0000269|PubMed:9218782, ECO:0000269|PubMed:9571151, ECO:0000269|Ref.44, ECO:0000269|Ref.45}.
Domain: The PH domain mediates the binding to inositol polyphosphate and phosphoinositides, leading to its targeting to the plasma membrane. It is extended in the BTK kinase family by a region designated the TH (Tec homology) domain, which consists of about 80 residues preceding the SH3 domain. {ECO:0000269|PubMed:10196129, ECO:0000269|PubMed:10196179, ECO:0000269|PubMed:11751885, ECO:0000269|PubMed:8070576}.
Subcellular location: Cytoplasm. Cell membrane; Peripheral membrane protein. Nucleus. Note=In steady state, BTK is predominantly cytosolic. Following B-cell receptor (BCR) engagement by antigen, translocates to the plasma membrane through its PH domain. Plasma membrane localization is a critical step in the activation of BTK. A fraction of BTK also shuttles between the nucleus and the cytoplasm, and nuclear export is mediated by the nuclear export receptor CRM1.
Tissue specificity: Predominantly expressed in B-lymphocytes.
Post-translational: Following B-cell receptor (BCR) engagement, translocates to the plasma membrane where it gets phosphorylated at Tyr-551 by LYN and SYK. Phosphorylation at Tyr-551 is followed by autophosphorylation of Tyr-223 which may create a docking site for a SH2 containing protein. Phosphorylation at Ser-180 by PRKCB, leads in translocation of BTK back to the cytoplasmic fraction. Phosphorylation at Ser-21 and Ser-115 creates a binding site for PIN1 at these Ser-Pro motifs, and promotes it's recruitment. {ECO:0000269|PubMed:11598012, ECO:0000269|PubMed:12573241, ECO:0000269|PubMed:15375214, ECO:0000269|PubMed:16644721, ECO:0000269|PubMed:17932028, ECO:0000269|PubMed:8630736, ECO:0000269|PubMed:9012831}.
Involvement in disease: DISEASE: X-linked agammaglobulinemia (XLA) [MIM:300755]: Humoral immunodeficiency disease which results in developmental defects in the maturation pathway of B-cells. Affected boys have normal levels of pre-B-cells in their bone marrow but virtually no circulating mature B-lymphocytes. This results in a lack of immunoglobulins of all classes and leads to recurrent bacterial infections like otitis, conjunctivitis, dermatitis, sinusitis in the first few years of life, or even some patients present overwhelming sepsis or meningitis, resulting in death in a few hours. Treatment in most cases is by infusion of intravenous immunoglobulin. {ECO:0000269|PubMed:10220140, ECO:0000269|PubMed:10612838, ECO:0000269|PubMed:10678660, ECO:0000269|PubMed:7627183, ECO:0000269|PubMed:7633420, ECO:0000269|PubMed:7633429, ECO:0000269|PubMed:7711734, ECO:0000269|PubMed:7809124, ECO:0000269|PubMed:7849006, ECO:0000269|PubMed:7849697, ECO:0000269|PubMed:7849721, ECO:0000269|PubMed:7880320, ECO:0000269|PubMed:7897635, ECO:0000269|PubMed:8013627, ECO:0000269|PubMed:8162018, ECO:0000269|PubMed:8162056, ECO:0000269|PubMed:8634718, ECO:0000269|PubMed:8695804, ECO:0000269|PubMed:8723128, ECO:0000269|PubMed:8834236, ECO:0000269|PubMed:9260159, ECO:0000269|PubMed:9280283, ECO:0000269|PubMed:9445504, ECO:0000269|PubMed:9545398}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: X-linked hypogammaglobulinemia and isolated growth hormone deficiency (XLA-IGHD) [MIM:307200]: In rare cases XLA is inherited together with isolated growth hormone deficiency (IGHD). Note=The disease may be caused by mutations affecting the gene represented in this entry.
Sequence similarity: Belongs to the protein kinase superfamily. Tyr protein kinase family. TEC subfamily. {ECO:0000255|PROSITE-ProRule:PRU00159}.; Contains 1 Btk-type zinc finger. {ECO:0000255|PROSITE-ProRule:PRU00432}.; Contains 1 PH domain. {ECO:0000255|PROSITE-ProRule:PRU00145}.; Contains 1 protein kinase domain. {ECO:0000255|PROSITE-ProRule:PRU00159}.; Contains 1 SH2 domain. {ECO:0000255|PROSITE-ProRule:PRU00191}.; Contains 1 SH3 domain. {ECO:0000255|PROSITE-ProRule:PRU00192}.
General information above from UniProt

Bruton's tyrosine kinase (or BTK) is a type of kinase protein expressed in B lymphocytes and T cells. BTK contains a PH domain which binds phosphatidylinositol(3,4,5)-trisphosphate (PIP3). After binding to PIP3, BTK is induced to phosphorylate phospholipase C, which in turn hydrolyzes PIP2 into two second messagers, IP3 and DAG, which then modulate the activity of downstream proteins during B-cell signaling. Btk is also found implicated in the primary immunodeficiency disease X-linked agammaglobulinemia(Bruton's agammaglobulinemia). BTK played a key role in B-cell maturation as well as mast cell activation through the high-affinity IgE receptor. Patients with X-linked agammaglobulinemia have normal pre-B cell populations in their bone marrow but these B-cells can not mature and enter the circulation.

Bruton Tyrosine Kinase / BTK Kinase Alternative Name

AT,ATK,BPK,XLA,IMD1,AGMX1,PSCTK1, [homo-sapiens]
BPK,MGC126261,MGC126262,PSCTK1,RP1-164F3.2,AGMX1,AT,ATK,BTK,IMD1,XLA, [human]
RP23-91G19.5,AI528679,Btk,xid, [mouse]
xid,AI528679, [mus-musculus]

Bruton Tyrosine Kinase / BTK Kinase Related Studies

  • Hashimoto S, et al. (1996) Identification of Bruton's tyrosine kinase (Btk) gene mutations and characterization of the derived proteins in 35 X-linked agammaglobulinemia families: a nationwide study of Btk deficiency in Japan. Blood. 88(2): 561-73.
  • Ohta Y, et al. (1994) Genomic organization and structure of Bruton agammaglobulinemia tyrosine kinase: localization of mutations associated with varied clinical presentations and course in X chromosome-linked agammaglobulinemia. PNAS. 91(19): 9062-6.
  • Smith C, et al. (1994) Expression of Bruton's agammaglobulinemia tyrosine kinase gene, BTK, is selectively down-regulated in T lymphocytes and plasma cells. The Journal of Immunology. 152(2): 557-65.